ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Impact of Early Antimalarial Adherence on Future Acute Care Utilization and Cost Among Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Population-Based Study.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo assess the association between early antimalarial adherence and future acute care utilization and cost in a population-based cohort of incident rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
methodsAll patients with incident RA/SLE and new antimalarial use in British Columbia, Canada, between January 1997 and March 2022 with at least one year of follow-up were identified using provincial administrative databases. Each antimalarial adherent patient (proportion of days covered [PDC] ≥ 0.90) was propensity score (PS) matched up to two antimalarial nonadherent patients (0 < PDC < 0.90). The outcomes hospital admissions, hospitalized days, and hospitalization cost were assessed in the following year. We estimated the impact of early antimalarial adherence on these outcomes, accounting for potential confounders, using quasi-Poisson and linear models with robust SEs. We conducted falsification tests and sensitivity analyses to examine robustness to healthy adherer effect and unmeasured confounders.
resultsWe identified 8,768 antimalarial adherent and 16,479 antimalarial nonadherent PS-matched individuals with RA/SLE. The adjusted rate ratios of hospital admissions and hospitalized days obtained for antimalarial adherent versus nonadherent patients were 0.89 (95% confidence interval [CI] 0.84-0.94) and 0.79 (95% CI 0.71-0.88), respectively. The adjusted average hospitalization costs were lower (estimate: CAD -$549.64, 95% CI -$896.05 to -$203.22, P < 0.01) for antimalarial adherent patients than nonadherent patients. Falsification tests and sensitivity analyses confirmed the robustness of the results.
conclusionAdherence to antimalarials in patients with RA and SLE was associated with a lower risk of hospital admission (11% reduction) and hospitalized days (21% reduction) and lower hospitalization costs (CAD $549.64 lower) compared to nonadherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.